康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06185 康希诺生物

休市中 10-30 16:08:08

25.780

-0.120

-0.46%

最高27.000	最低25.200	成交量344.94万
今开26.000	昨收25.900	日振幅6.95%
总市值63.69亿	流通市值34.20亿	总股本2.47亿
成交额8,987万	换手率2.60%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":25.78,"timestamp":1793347688007,"preClose":25.9,"halted":0,"volume":3449400,"delay":0,"changeRate":-0.004633204633204535,"floatShares":132670900,"shares":247043801,"eps":0.1297559157670098,"marketStatus":"休市中","change":-0.12,"latestTime":"10-30 16:08:08","open":26,"high":27,"low":25.2,"amount":89874576,"amplitude":0.069498,"askPrice":25.78,"askSize":62600,"bidPrice":25.64,"bidSize":7400,"shortable":3,"etf":0,"ttmEps":0.1417017172122144,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":7,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":25.9,"openAndCloseTimeList":[[1793323800000,1793332800000],[1793336400000,1793347200000]],"volumeRatio":0.792541917272976,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":72.75,"timestamp":1793343600000,"preClose":73.8,"halted":0,"volume":9348800,"delay":0,"premium":"-69.96"}},"requestUrl":"/m/hq/s/06185","defaultTab":"news","newsList":[{"id":"1122839011","title":"异动解读｜康希诺生物盘中上涨6.1%，前三季度营收与净利双增提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1122839011","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122839011?lang=zh_cn&edition=full","pubTime":"2026-10-28 13:21","pubTimestamp":1793164895,"startTime":"0","endTime":"0","summary":"10月28日，康希诺生物盘中上涨6.1%，报29.2港元，成交额8151.65万港元。消息面上，公司披露前三季度实现营业收入8.82亿元，同比增长27.40%；归母净利润1629.13万元，同比增长12.82%，业绩增长对股价形成支撑。进一步看，第三季度单季营收3.32亿元，同比增长7.17%；前三季度非经常性损益收益6126.85万元，研发投入2.60亿元，占营收比重29.42%。此外，公司首批限制性股票归属81.13万股，并称减值及递延所得税资产减记合计影响净利3303万元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物盘中上涨，前三季营收净利双增","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175626049","title":"康希诺生物首批限制性股票归属81.13万股 前三季度计提减值及递延税资产共影响净利3303万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175626049","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175626049?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:56","pubTimestamp":1793102171,"startTime":"0","endTime":"0","summary":"根据决议，公司将自2025年10月27日起的12个月后首个交易日起至24个月内的最后一个交易日，为85名激励对象办理限制性股票归属手续，归属数量合计811,320股，占首次授予限制性股票总量的40%。康希诺生物表示，本次限制性股票归属及部分作废事项不会对公司核心团队稳定性和激励计划的持续实施产生不利影响；本期计提的各项减值及递延所得税资产减记符合《企业会计准则》要求，客观反映了公司截至2026年9月30日的财务状况。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198128970","title":"康希诺生物（06185）发布三季报：前三季度营收8.82亿元 同比增27.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198128970","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198128970?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:31","pubTimestamp":1793100683,"startTime":"0","endTime":"0","summary":"2026年10月27日，康希诺生物股份公司披露截至2026年9月30日止九个月未经审计的第三季度报告。报告期内，公司实现营业收入8.82亿元，较上年同期增长27.40%。其中，第三季度单季实现营业收入3.32亿元，同比增加7.17%。非经常性损益方面，报告期内公司实现收益6,126.85万元，主要包括政府补助2,360.00万元、公允价值变动及处置金融资产收益2,739.78万元等。报告期内公司研发投入合计2.60亿元，同比减少5.33%，占营业收入比重为29.42%；第三季度研发投入9,369.08万元，占季度营收的28.18%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678171615","title":"康希诺生物(06185.HK)前三季度归母净利润1629.13万元 同比增长12.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678171615","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678171615?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:29","pubTimestamp":1793100574,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1191","BK1515","BK1574","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678050179","title":"康希诺生物前三季度业绩增长：多产品商业化提速，平台化创新打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2678050179","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678050179?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:24","pubTimestamp":1793100256,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","BK1515","BK1574","BK1161","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141065920","title":"异动解读｜康希诺生物盘中下跌5.1%，莫得纳癌症疫苗数据扰动mRNA概念情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1141065920","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141065920?lang=zh_cn&edition=full","pubTime":"2026-10-27 13:19","pubTimestamp":1793078355,"startTime":"0","endTime":"0","summary":"10月27日，康希诺生物盘中下跌5.1%，报27.52港元，成交额3876.27万港元。消息面上，市场此前对海外mRNA肿瘤疫苗临床数据抱有较高预期，但莫得纳与默克联合研发的个性化黑色素瘤疫苗三期试验数据提前泄露且未达高预期，压制了相关概念股情绪。公司已搭建mRNA开发和制备平台，并曾与德普世生物签署合作框架协议，共同开发mRNA个性化肿瘤疫苗；此前公司亦提示，海外mRNA肿瘤疫苗阶段性数据发布可能影响市场波动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物下跌，mRNA疫苗数据扰动情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677916587","title":"港股异动 | 康希诺生物跌逾5%，莫得纳癌症疫苗试验数据泄露未达市场高预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2677916587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677916587?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:51","pubTimestamp":1792720293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，$康希诺生物(06185)$(06185)跌逾 5%。消息面上，隔夜美股莫得纳大跌逾17%，其与默克联合研发的个性化黑色素瘤疫苗三期临床试验数据意外提前泄露，结果未达市场今年早些时候形成的高预期。今年8月，莫得纳宣布这款定制疫苗如与默克畅销药Keytruda联合使用，可显著降低这种致命肿瘤的复发风险，并具有临床意义。据悉，$康希诺(688185)$已搭建mRNA开发和制备平台，公司旗下康希诺上海此前与德普世$生物(000504)$签署合作框架协议，共同开发mRNA个性化肿瘤疫苗，由康希诺提供mRNA递送及制剂能力，德普世提供AI新抗原发现和设计平台。","market":"hk","thumbnail":"https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511249.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"莫得纳癌症疫苗试验数据泄露未达市场高预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SPAM","VXUS","KCAI","BK4585","CRWC","PSWD","UCYB","BK1191","06185","HAKY","159646","BK4588","BK1515","BK1574","CRWL","WCBR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677163559","title":"港股异动 | 康希诺生物(06185.HK)一度跌近8% 莫得纳癌症疫苗试验数据泄露未达市场高预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2677163559","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677163559?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:39","pubTimestamp":1792719594,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1515","BK1191","BK1161","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134991246","title":"异动解读｜康希诺生物盘中下跌6.15%，业绩窗口临近叠加生物科技板块承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1134991246","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134991246?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:32","pubTimestamp":1792719166,"startTime":"0","endTime":"0","summary":"10月23日，康希诺生物盘中下跌6.15%，报27.0港元，成交额986.8万港元。消息面上，公司将于10月27日召开董事会审议第三季度业绩，市场进入季报窗口；同时生物科技板块整体偏弱，对股价形成压制。但当日同行中云顶新耀跌8.89%，信达生物跌0.92%，康方生物跌0.95%，板块波动放大了个股调整。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物盘中下挫，季报窗口叠加板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121845717","title":"异动解读｜康希诺生物盘中下跌5.12%，业绩窗口临近下板块承压波动","url":"https://stock-news.laohu8.com/highlight/detail?id=1121845717","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121845717?lang=zh_cn&edition=full","pubTime":"2026-10-22 13:23","pubTimestamp":1792646608,"startTime":"0","endTime":"0","summary":"10月22日，康希诺生物盘中下跌5.12%，报28.56港元，成交额4786.78万港元。从公开信息看，公司将于10月27日召开董事会审议第三季度业绩，市场正进入季报窗口。公司此前中期营收5.47亿元，同比增长46.1%，经调整净亏损收窄至72.10万元；10月中旬公司还披露收到286.63万元政府补助，预计对利润产生积极影响。不过，当日生物科技板块整体偏弱，康方生物跌9.43%，信达生物跌7.86%，百济神州跌2.68%，三生制药跌4.9%，板块波动对个股形成压制。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"业绩窗口临近，康希诺生物盘中下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138849513","title":"异动解读｜康希诺生物盘中上涨5.53%，行业情绪修复叠加季报窗口临近","url":"https://stock-news.laohu8.com/highlight/detail?id=1138849513","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138849513?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:33","pubTimestamp":1792546421,"startTime":"0","endTime":"0","summary":"10月21日，康希诺生物盘中上涨5.53%，报30.58港元，成交额1338.85万港元。消息面上，市场近期围绕生物医药技术出口目录修订的担忧有所缓和。公开解读显示，相关政策主要针对底层平台技术所有权转让，不涉及外包研发生产服务及常规对外授权，医药板块情绪出现修复。公司层面，康希诺生物已公告将于10月27日召开董事会审议前三季度业绩。此前其中期营收为5.47亿元，同比增长46.1%，经调整净亏损收窄至72.10万元，业绩窗口临近也提升了市场关注度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物盘中上涨，季报窗口临近引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677643406","title":"【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2677643406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677643406?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:16","pubTimestamp":1792545406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指出，创新药前沿技术加速迭代，IO2.0、ADC迭代、自免长效双抗等重塑治疗格局。中国原研资产深度融入全球交易，国际化步入收获期。支付端医保与商保双轮驱动，国谈优化准入，商保目录落地缓解高值药进院约束，本土Biotech净现金流改善、迎来盈亏平衡拐点。海内外政策聚焦真创新，生物类似药温和集采兑现。优质管线梯队完备，百济神州、康方生物、科伦博泰等核心分子加速欧美商业化，创新药板块迎来业绩兑现与国际化重估共振。风险提示：BD受海外地缘政策约束风险；创新药行业竞争加剧风险；医保控费降价不及预期风险；海外流动性收紧风险。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","LU1807302812.USD","BK1141","01801","LU0348783233.USD","LU0588546209.SGD","01177","09688","09926","BK1574","IE00B0JY6N72.USD","01093","LU0880133367.SGD","LU1226288170.HKD","LU1770034418.SGD","LU2097828714.EUR","MEDX","02142","LU0540923850.HKD","LU0348784397.USD","IE0008368742.USD","IE00BPRC5H50.USD","LNGR","LU0456846285.SGD","LU1794554557.SGD","06160","02616","LU0228659784.USD","LU0128526141.USD","LU0823426308.USD","IBBQ","LU0417516571.SGD","159992","01877","LU0320764599.SGD","IE00B031HY20.USD","KURE","09995","LU0128522744.USD","LU1951186391.HKD","600109","02269","06978","KCE","LU0516422366.SGD","LU1303224171.USD","LU0516422440.USD","LU0455707207.USD","BK1589","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146647715","title":"异动解读｜康希诺生物盘中上涨6.44%，董事会将审议第三季度业绩带动关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1146647715","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146647715?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:36","pubTimestamp":1792114579,"startTime":"0","endTime":"0","summary":"10月16日，康希诺生物盘中上涨6.44%，报32.58港元，成交额4383.37万港元。消息面上，公司已公告将于10月27日召开董事会，审议并批准截至9月30日止九个月的第三季度业绩及其发布事宜，临近财报窗口提升市场关注度。此前公司上半年营收约5.47亿元，同比增长46.1%，经调整净亏损收窄至72.10万元；近期又收到286.63万元政府补助并计入当期收益，预计对利润产生积极影响，但最终影响仍以审计结果为准。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物异动上涨，三季报审议在即","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU1969619763.USD","09688","601066","BK1141","BK1583","LU0314109678.HKD","LU0228659784.USD","09995","LU1951186391.HKD","LU1226287792.SGD","LU1226287875.USD","LU0979878070.USD","LU0634319403.HKD","09926","LU0052750758.USD","KURE","LU0823426480.USD","LU0501845795.SGD","02269","KCE","LU0417516902.SGD","06185","BK1515","06160","01801","LU0072913022.USD","LU0140636845.USD","LU0819121731.USD","SG9999011746.SGD","BK1500","SG9999002562.SGD","LU1251922891.USD","09939","LU0128526141.USD","LU0540923850.HKD","01093","LU0348827113.USD","159938","LU0326950275.SGD","02616","LU2476274720.SGD","01177","BK1610","02142","IE00BZ08YR35.GBP","LU0181495838.USD","LU0348767384.USD","LU1242518857.USD","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675376082","title":"【券商聚焦】中信建投：AI重塑药物研发 2035年全球市场有望破460亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376082","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376082?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:00","pubTimestamp":1792026019,"startTime":"0","endTime":"0","summary":"AI深度介入靶点识别、分子设计等药物研发环节，破解传统制药高投入、长周期难题。报告测算，全球AI制药市场2025年规模约24.9亿美元，2035年有望突破460亿美元，CAGR超33%，国内市场具备高增长潜力；科技巨头、药企、CXO等多方入局，海内外多家头部企业完成平台搭建与商业化验证。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU1152091754.HKD","02269","LU0501845795.SGD","LU0052750758.USD","LU0128526141.USD","LU0128522744.USD","LU0456827905.SGD","01801","BK1576","IE00B031HY20.USD","01877","LU0456846285.SGD","LU0979878070.USD","LU0326950275.SGD","02616","LU2242644610.SGD","IBBJ","LU0029874061.USD","LU0588546209.SGD","LU0516422440.USD","BK1588","601066","VTHR","LU0856984785.SGD","LU0051755006.USD","LU1008478684.HKD","06185","09688","09926","01093","AIPO","02142","KCE","LU1251922891.USD","CHAT","LU0516422952.EUR","AGIX","SG9999002562.SGD","BK1500","BK1141","LU2778985437.USD","09995","KURE","IE00BZ08YS42.EUR","ARTY","01177","06160","QTOC","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131391178","title":"康希诺生物(06185)拟于10月27日召开董事会审议2026年第三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1131391178","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131391178?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:35","pubTimestamp":1791966932,"startTime":"0","endTime":"0","summary":"康希诺生物股份公司（06185）10月14日在港交所公告称，董事会已排定于2026年10月27日（星期二）召开会议，届时将审议并批准公司及其附属公司截至2026年9月30日止九个月的第三季度业绩及其发布事宜。\n公告显示，截至本通告日期，康希诺生物董事会成员包括：执行董事——Xuefeng YU博士、Shou Bai CHAO博士及王靖女士；非执行董事——李志成先生；独立非执行董事——张耀梁先生、左敏先生及纪雪峰女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154793946","title":"康希诺生物（06185）获286.63万元政府补助 占上年净利10.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154793946","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154793946?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:05","pubTimestamp":1791795932,"startTime":"0","endTime":"0","summary":"2026年10月13日，康希诺生物股份公司（06185）公告称，公司近期收到政府补助款286.63万元，并已确认为当期收益。\\n\\n公告显示，286.63万元的补助占公司最近一个会计年度经审计净利润的10.28%。\\n\\n康希诺生物依据《企业会计准则第16号——政府补助》对该款项进行会计处理。公司提示，具体会计处理及对公司损益的最终影响仍以年度审计结果为准。\\n\\n公司表示，上述补助预计将对利润产生积极影响，并提醒投资者注意投资风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114435114","title":"异动解读｜康希诺生物盘中上涨5.31%，疫苗板块情绪修复带动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1114435114","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114435114?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:30","pubTimestamp":1791768659,"startTime":"0","endTime":"0","summary":"10月12日，康希诺生物盘中上涨5.31%，报36.82港元，成交额954.62万港元。消息面上，经历此前连续多个交易日回调后，港股创新药及疫苗板块出现情绪修复，康希诺生物作为前期活跃的mRNA疫苗概念股获得资金回流。公司基本面方面，其与德普世生物合作的mRNA个性化肿瘤疫苗仍处于早期开发阶段，但海外收入在上半年同比增长超47倍，国际化业务成为重要增长引擎。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物上涨，疫苗板块情绪修复","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192955614","title":"异动解读｜康希诺生物盘中下跌5.34%，莫德纳暴跌与获利回吐双重压制","url":"https://stock-news.laohu8.com/highlight/detail?id=1192955614","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192955614?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:39","pubTimestamp":1791509942,"startTime":"0","endTime":"0","summary":"10月9日，康希诺生物盘中下跌5.34%，报34.02港元，成交额3311.58万港元。消息面上，隔夜美股疫苗巨头莫德纳暴跌，加上花旗将莫德纳评级下调至卖出，负面情绪跨市场传导至港股疫苗及创新药板块。此前受ESMO年会数据预期提振，康希诺生物在国庆期间连续大涨，累计涨幅较大，短期获利盘回吐压力显著。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司，产品主要应用于脑膜炎、百白破和肺炎领域，业务涵盖创新疫苗研发、生产及商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物回调，莫德纳暴跌拖累情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143555120","title":"异动解读｜康希诺生物盘中下跌5.21%，莫德纳暴跌拖累疫苗板块获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1143555120","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143555120?lang=zh_cn&edition=full","pubTime":"2026-10-08 15:27","pubTimestamp":1791444449,"startTime":"0","endTime":"0","summary":"10月8日，康希诺生物盘中下跌5.21%，报36.02港元，成交额3.77亿港元。隔夜美股疫苗巨头莫德纳暴跌8%，叠加花旗将莫德纳评级下调至卖出，情绪跨市场传导直接拖累港股疫苗及相关创新药板块。此前受益于ESMO年会数据预期，康希诺生物在国庆期间连续大涨，累计涨幅较大，短期获利盘回吐压力凸显。公司与德普世生物合作的mRNA个性化肿瘤疫苗仍处于早期开发阶段，市场对短期估值兑现趋于谨慎。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司，产品主要应用于脑膜炎、百白破和肺炎领域，业务涵盖创新疫苗研发、生产及商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物随莫德纳走弱，疫苗板块获利回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":-0.0903},{"period":"1month","weight":-0.2945},{"period":"3month","weight":0.1074},{"period":"6month","weight":-0.1225},{"period":"1year","weight":-0.4178},{"period":"ytd","weight":-0.2617}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0536},{"period":"3month","weight":-0.1001},{"period":"6month","weight":-0.0963},{"period":"1year","weight":-0.1137},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.030578},{"month":2,"riseRate":0.857143,"avgChangeRate":0.172684},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.060436},{"month":4,"riseRate":0.625,"avgChangeRate":0.049828},{"month":5,"riseRate":0.25,"avgChangeRate":-0.051769},{"month":6,"riseRate":0.5,"avgChangeRate":0.015607},{"month":7,"riseRate":0.625,"avgChangeRate":0.054796},{"month":8,"riseRate":0.25,"avgChangeRate":-0.091996},{"month":9,"riseRate":0.75,"avgChangeRate":0.089616},{"month":10,"riseRate":0.375,"avgChangeRate":0.014968},{"month":11,"riseRate":0.571429,"avgChangeRate":0.088604},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.035813}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}